PURPOSE: To evaluate long-term outcome of cavernous sinus meningioma (CSM) treated with fractionated conformal radiotherapy (FCR). PATIENTS AND METHODS: Fifty-three patients with CSMs (16 men [30.2%], 37 women [69.8%], aged 53 ± 13.0 years [mean ± SD]) were treated by FCR. In 28 patients (52.8%) FCR was performed as first-line treatment and in 25 patients (47.2%) as adjuvant treatment. All patients received FCR with a dose of 52.9 ± 1.8 Gy in 29.4 ± 1.0 fractions over 6 weeks. Dose per fraction was 1.9 ± 0.1 Gy. Radiotherapy was delivered stereotactically in 47 cases (88.7%) and conformally in 6 (11.3%) RESULTS: The median follow-up was 6.9 years (range, 3-19 years). According to Sekhar's classification, 19 patients (35.8%) were Grade 1-2, 30 patients (56.6%) were Grade 3-4, and 4 patients (7.6%) were Grade 5. Pretreatment tumor volume was determined in 46 patients, and tumor volume was 12.6 ± 8.2 cm(3). In these patients, the distance between tumor and optic apparatus was 1.62 ± 1.2 mm. Actuarial 5- and 10-year progression-free survival rates were 98.1% and 95.8%, respectively. Clinical improvement was observed in 31 patients (58.5%), and 20 patients (37.7%) remained unchanged. Radiologic response was observed in 18 patients (30.2%), and 35 patients (66.0%) showed stable lesions. Two patients (3.8%) showed tumor progression during follow-up. Transient morbidity was observed in 3 patients (5.7%) and permanent morbidity in 1 (1.9%). CONCLUSION: Fractionated conformal radiotherapy affords satisfactory long-term tumor control and low treatment morbidity.
PURPOSE: To evaluate long-term outcome of cavernous sinus meningioma (CSM) treated with fractionated conformal radiotherapy (FCR). PATIENTS AND METHODS: Fifty-three patients with CSMs (16 men [30.2%], 37 women [69.8%], aged 53 ± 13.0 years [mean ± SD]) were treated by FCR. In 28 patients (52.8%) FCR was performed as first-line treatment and in 25 patients (47.2%) as adjuvant treatment. All patients received FCR with a dose of 52.9 ± 1.8 Gy in 29.4 ± 1.0 fractions over 6 weeks. Dose per fraction was 1.9 ± 0.1 Gy. Radiotherapy was delivered stereotactically in 47 cases (88.7%) and conformally in 6 (11.3%) RESULTS: The median follow-up was 6.9 years (range, 3-19 years). According to Sekhar's classification, 19 patients (35.8%) were Grade 1-2, 30 patients (56.6%) were Grade 3-4, and 4 patients (7.6%) were Grade 5. Pretreatment tumor volume was determined in 46 patients, and tumor volume was 12.6 ± 8.2 cm(3). In these patients, the distance between tumor and optic apparatus was 1.62 ± 1.2 mm. Actuarial 5- and 10-year progression-free survival rates were 98.1% and 95.8%, respectively. Clinical improvement was observed in 31 patients (58.5%), and 20 patients (37.7%) remained unchanged. Radiologic response was observed in 18 patients (30.2%), and 35 patients (66.0%) showed stable lesions. Two patients (3.8%) showed tumor progression during follow-up. Transient morbidity was observed in 3 patients (5.7%) and permanent morbidity in 1 (1.9%). CONCLUSION: Fractionated conformal radiotherapy affords satisfactory long-term tumor control and low treatment morbidity.
Authors: Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum Journal: J Neurosurg Date: 2015-01 Impact factor: 5.115
Authors: Andrew Faramand; Hideyuki Kano; Ajay Niranjan; Stephen A Johnson; Mohab Hassib; Kyung-Jae Park; Yoshio Arai; John C Flickinger; L Dade Lunsford Journal: J Neurooncol Date: 2018-04-24 Impact factor: 4.130
Authors: Indrawati Hadi; Annamaria Biczok; Nicole Terpolilli; Jun Thorsteinsdottir; Robert Forbrig; Nathalie L Albert; Petar Yanchovski; Barbara Zollner; Raphael Bodensohn; Stefanie Corradini; Peter Bartenstein; Claus Belka; Jörg-Christian Tonn; Christian Schichor; Maximilian Niyazi Journal: Neurooncol Adv Date: 2021-08-20
Authors: Antonio Santacroce; Constantin Tuleasca; Roman Liščák; Enrico Motti; Christer Lindquist; Matthias Radatz; Brigitte Gatterbauer; Bodo E Lippitz; Roberto Martínez Álvarez; Nuria Martínez Moreno; Marcel A Kamp; Bente Sandvei Skeie; Stephanie Schipmann; Michele Longhi; Frank Unger; Ian Sabin; Thomas Mindermann; Otto Bundschuh; Gerhard A Horstmann; A T C J van Eck; Maja Walier; Manfred Berres; Makoto Nakamura; Hans Jakob Steiger; Daniel Hänggi; Thomas Fortmann; Samer Zawy Alsofy; Jean Régis; Christian Ewelt Journal: Cancers (Basel) Date: 2022-08-22 Impact factor: 6.575